Delivery Order 36F79725D0146-36C24526N0647
Award Date 6/12/26
Potential Completion Date 6/16/26
Potential Value $23K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Carrollton, TX 75010, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, Veterans Integrated Service Network 5, issued a delivery order to Merck Sharp & Dohme LLC on May 21, 2026, for Welireg (belzutifan) 40 mg with a ceiling value of $22,508.03. The order is issued under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB), a $5.84 billion Federal Supply Schedule contract with the Department of Veterans Affairs extending through May 31, 2030. Place of performance is Carrollton, TX. The order has a firm fixed price...
- Merck Sharp & Dohme LLC was awarded a delivery order valued at $22,508.03 for WELIREG (belzutifan) 40 mg under the Department of Veterans Affairs' Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB). The award is effective as of April 15, 2026, with an ultimate completion date of April 16, 2026, and will be performed in Carrollton, Texas. This delivery order was issued under firm fixed pricing with no set-aside designation and represents a continuation of Merck's role as a...
- Merck Sharp & Dohme LLC was awarded a delivery order valued at $44.1M for WELIREG (belzutifan) 40 mg tablets by the Department of Veterans Affairs, specifically Veterans Integrated Service Network 20. This firm fixed-price delivery order, issued on February 10, 2025, with an ultimate completion date of September 30, 2025, represents procurement of an oncology therapeutic used in the treatment of renal cell carcinoma. The award is issued under Merck's parent Federal Supply Schedule contract...
- This is a firm fixed-price delivery order awarded by the Veterans Integrated Service Network 21 (VISN 21) of the U.S. Department of Veterans Affairs to Merck Sharp & Dohme LLC, doing business as Merck, a major pharmaceutical manufacturer. The order is for the drug Welireg (belzutifan) 40mg tablets, National Drug Code 00006-5331-01. The award has a ceiling value of $19,964.86 and an ultimate completion date of July 10, 2024. This delivery order falls under Merck's prime contract on the...
- Merck Sharp & Dohme LLC (Merck) received a delivery order award from Veterans Integrated Service Network 20 (VISN 20), an operational component of the Department of Veterans Affairs, for the 2025 price increase associated with Welireg (belzutifan), a pharmaceutical treatment for renal cell carcinoma. The contract, awarded on August 28, 2024, carries a ceiling value of $64,067.64 under firm fixed-price terms with an ultimate completion date of August 28, 2025. This delivery order is issued...
- This federal contract award is for the delivery of Belzutifan (Welireg) 40 mg, a pharmaceutical product, to the U.S. Department of Veterans Affairs (VA). The contract was awarded to Merck Sharp & Dohme LLC, doing business as Merck, a major pharmaceutical manufacturer and supplier to the federal government. The contract is a Delivery Order under Merck's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs. It has a firm fixed price of $19,964.86 and a completion date of...
- The Department of Veterans Affairs Veterans Health Administration awarded a $19,964.86 firm-fixed-price delivery order contract to Merck Sharp & Dohme LLC, doing business as Merck, for the pharmaceutical drug Welireg (Belzutifan) 40mg tablets. This award is under Merck's existing General Services Administration Federal Supply Schedule (FSS-61-IB) contract for pharmaceuticals and drugs. The contract has a completion date of June 7, 2024. Merck is a major pharmaceutical manufacturer that has...
- This is a $19,964.86 firm fixed-price delivery order contract awarded by the Department of Veterans Affairs to Merck Sharp & Dohme LLC, doing business as Merck, a major pharmaceutical manufacturer. The contract is for the supply of the drug Welireg (belzutifan), which is used in the treatment of certain types of cancer. The contract has an ultimate completion date of November 12, 2024. Merck is a for-profit organization that has been a long-standing supplier to various federal agencies,...
- This federal contract award was made by the Veterans Integrated Service Network 20 (VISN 20) to Merck Sharp & Dohme LLC, doing business as Merck, a major pharmaceutical manufacturer. The contract is for the delivery of the cancer drug Welireg (belzutifan) and is a Firm Fixed Price Delivery Order under Merck's Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract. The contract has a ceiling value of $59,894.58 and a period of performance ending on January 31, 2025. The...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a $17,046 firm fixed price delivery order against GSA Schedule Pharmaceuticals and Drugs (FSS-61-IB) to Janssen Biotech, Inc. to provide BALVERSA 4MG. The place of performance is Carrollton, Texas. The period of performance is September 13-14, 2023. This delivery order supports the VA's mission to provide healthcare services to veterans through its Veterans Integrated Service Network...